Study on diagnostic efficacy of combined detection of serum CCL-18, p185 and SDF-1 in breast cancer

This study aims to investigate the diagnostic efficacy of combined detection of serum C-C Motif Chemokine 18 (CCL-18), p185 and Stromal cell derived factor 1 (SDF-1) in breast cancer. 88 breast cancer patients admitted to our hospital were selected as study subjects. 88 healthy women who visited for a physical examination during the same period were selected as controls. Serum CCL-18, p185 and SDF-1 levels were measured. Combined detection and single detection in breast cancer diagnosis were compared in terms of sensitivity, specificity, accuracy, positive predictive value and negative predictive value. ROC (receiver operating characteristic) curves were drawn to further compare the differences between combined detection and single detection methods. CCL-18, p185 and SDF-1 in the cancer group were significantly higher than in the control group (p < 0.05). The area under the ROC curve of CCL-18, p185, SDF-1 and combined detection were 0.786 (95% Confidence Interval (CI): 0.717–0.854), 0.852 (95% CI: 0.788–0.916), 0.921 (95% CI: 0.883–0.958) and 0.962 (95% CI: 0.925–0.999), respectively. Sensitivity of combined detection was significantly higher than CCL-18 and p185 (p < 0.05). Specificity, accuracy and positive predictive value of combined detection were significantly higher than CCL-18, p185 and SDF-1 (p < 0.05). Compared with CCL-18 and p185, combined detection had a higher negative predictive value, which was statistically significant (p < 0.05). Combined detection of serum CCL-18, p185 and SDF-1 is more effective at diagnosing breast cancer and is worth clinical application.

CCL-18; p185; SDF-1; Combined detection; Breast cancer; Diagnostic efficacy

[1] Zubair M, Wang S, Ali N. Advanced approaches to breast cancer classification and diagnosis. Frontiers in Pharmacology. 2021; 11: 632079.

[2] Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Annals of Oncology. 2023; 34: 645–659.

[3] Hester RH, Hortobagyi GN, Lim B. Inflammatory breast cancer: early recognition and diagnosis is critical. American Journal of Obstetrics and Gynecology. 2021; 225: 392–396.

[4] Nguyen SM, Nguyen QT, Nguyen LM, Pham AT, Luu HN, Tran HTT, et al. Delay in the diagnosis and treatment of breast cancer in Vietnam. Cancer Medicine. 2021; 10: 7683–7691.

[5] Esmaeilzadeh M, Urzua Fresno CM, Somerset E, Shalmon T, Amir E, Fan CS, et al. A combined echocardiography approach for the diagnosis of cancer therapy—related cardiac dysfunction in women with early-stage breast cancer. JAMA Cardiology. 2022; 7: 330–340.

[6] Zhao D, Xu M, Yang S, Ma H, Li H, Wu R, et al. Specific diagnosis of lymph node micrometastasis in breast cancer by targeting activatable near-infrared fluorescence imaging. Biomaterials. 2022; 282: 121388.

[7] Ding R, Xiao Y, Mo M, Zheng Y, Jiang YZ, Shao ZM. Breast cancer screening and early diagnosis in Chinese women. Cancer Biology & Medicine. 2022; 19: 450–467.

[8] Dileep G, Gianchandani Gyani SG. Artificial intelligence in breast cancer screening and diagnosis. Cureus. 2022; 14: e30318.

[9] Sitia L, Sevieri M, Signati L, Bonizzi A, Chesi A, Mainini F, et al. HER-2-targeted nanoparticles for breast cancer diagnosis and treatment. Cancers. 2022; 14: 2424.

[10] Chen W, Li Z, Deng P, Li Z, Xu Y, Li H, et al. Advances of exosomal miRNAs in breast cancer progression and diagnosis. Diagnostics. 2021; 11: 2151.

[11] Tian J, Zhang J. Breast cancer diagnosis using feature extraction and boosted C5.0 decision tree algorithm with penalty factor. Mathematical Biosciences and Engineering. 2022; 19: 2193–2205.

[12] Moyya PD, Asaithambi M. Radiomics—quantitative biomarker analysis for breast cancer diagnosis and prediction: a review. Current Medical Imaging Formerly Current Medical Imaging Reviews. 2022; 18: 3–17.

[13] Kang D, Kim N, Han G, Kim S, Kim H, Lim J, et al. Divorce after breast cancer diagnosis and its impact on quality of life. Palliative and Supportive Care. 2022; 20: 807–812.

[14] Vegunta S, Kuhle CL, Vencill JA, Lucas PH, Mussallem DM. Sexual health after a breast cancer diagnosis: addressing a forgotten aspect of survivorship. Journal of Clinical Medicine. 2022; 11: 6723.

[15] Daniel O, Ashrafi A, Muthoni MA, Njoki N, Eric H, Marilynn O, et al. Delayed breast cancer presentation, diagnosis, and treatment in Kenya. Breast Cancer Research and Treatment. 2023; 202: 515–527.

[16] An J, Hershberger PE, Ferrans CE. Delayed presentation, diagnosis, and treatment of breast cancer among Chinese women. Cancer Nursing. 2023; 46: 217–232.

[17] Cui S, Liu W, Wang W, Miao K, Guan X. Advances in the diagnosis and prognosis of minimal residual lesions of breast cancer. Pathology—Research and Practice. 2023; 245: 154428.

[18] Loric S, Denis JA, Desbene C, Sabbah M, Conti M. Extracellular vesicles in breast cancer: from biology and function to clinical diagnosis and therapeutic management. International Journal of Molecular Sciences. 2023; 24: 7208.